Scientists created novel therapeutics using transmembrane stem cell factor (tmSCF) embedded in proteoliposomes or lipid nanodiscs. Mouse models of anaphylaxis and ischemia revealed the tmSCF-based therapies did not activate mast cells and improved the revascularization in the ischemic hind limb.
[Nature Communications]
